Highlights Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:00:42 2025-03-25 am EDT			5-day change	1st Jan Change
33.84 ^USD	-1.17%		-3.02%	-1.98%

Mar. 24	Harmony Biosciences Names Adam Zaeske As Chief Commercial Officer	RE
Mar. 24	Harmony Biosciences Holdings, Inc. Announces Executive Changes	CI

Highlights

Harmony Biosciences' Q4 Adjusted Earnings, Net Product Revenue Rise	Feb. 25	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	Feb. 25	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	Feb. 25	CI
Earnings Flash (HRMY) Harmony Biosciences Posts Q4 Net Product Revenue $201.3M, vs. FactSet Est of $201M	Feb. 25	MT
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Full Year 2025	Feb. 25	CI
Earnings Flash (HRMY) Harmony Biosciences Holdings Posts Q4 Adjusted EPS $1.08	Feb. 25	MT
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia	Feb. 19	CI
BofA Adjusts Price Target on Harmony Biosciences to $31 From $32	Feb. 03	MT
Harmony Biosciences Reports Preliminary Q4, 2024 Net Product Revenue; 2025 Revenue Guidance Issued	Jan. 13	MT
Harmony Biosciences Holdings, Inc. Announces Preliminary, Unaudited Net Product Revenues for the Fourth Quarter and Full Year Ended December 31, 2024	Jan. 13	CI
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2025	Jan. 13	CI
Harmony Biosciences Holdings Launches Secondary Common Stock Offering	24-10-30	MT
Harmony Biosciences Holdings Q3 Adjusted Earnings, Net Product Revenue Increase	24-10-29	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	24-10-29	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	24-10-29	CI
Harmony Biosciences Holdings, Inc. Re-Iterates Revenue Guidance for the Full Year 2024	24-10-29	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Reports Q3 EPS $1.03	24-10-29	MT
Harmony Biosciences Boosted by Narcolepsy Treatment, Diversification Outlook. UBS Says	24-09-10	MT
UBS Initiates Harmony Biosciences Holdings at Buy With $56 Price Target	24-09-10	MT
Harmony Biosciences' Q2 Adjusted EPS, Revenue Rise; Shares Gain	24-08-06	MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	24-08-06	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-06	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q2 EPS $0.20, vs. Street Est of $0.12	24-08-06	MT
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	24-08-06	CI
Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration Action Deny the Citized Petition for WAKIX®?	24-06-25	CI

894b0d16c2cf5bb2cd74220b22997.vABoIuX1V9K0pWW5-KE-PzlwGmYGheVCLno-Fn1a4g4.73A-dJ2-b5Hf9VDbvuZaS1skaTlv1bRzGwtuZjQqinfXdiJInJdin9z3NA

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Highlights

Filters